Hürthle cell carcinoma: a 60-year experience
The aim of this study was to define the clinical behavior and prognostic indicators of outcome in Hürthle cell cancer (HCC). Diagnosis was confirmed for 56 patients with HCC treated between 1940 and 2000, who form the basis of this study. Primary end points were relapse-free survival (RFS) and disea...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2002-03, Vol.9 (2), p.197-203 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 203 |
|---|---|
| container_issue | 2 |
| container_start_page | 197 |
| container_title | Annals of surgical oncology |
| container_volume | 9 |
| creator | Stojadinovic, Alexander Hoos, Axel Ghossein, Ronald A Urist, Marshall J Leung, Denis H Y Spiro, Ronald H Shah, Jatin P Brennan, Murray F Singh, Bhuvanesh Shaha, Ashok R |
| description | The aim of this study was to define the clinical behavior and prognostic indicators of outcome in Hürthle cell cancer (HCC).
Diagnosis was confirmed for 56 patients with HCC treated between 1940 and 2000, who form the basis of this study. Primary end points were relapse-free survival (RFS) and disease-specific survival (DSS). Data were analyzed with the Kaplan-Meier method and by log-rank test.
The extent of thyroid resection did not predict outcome. Recurrence was a significant predictor of tumor-related mortality. Significant adverse predictors of RFS and DSS were degree of invasion, size >4 cm, extrathyroidal extension, and initial nodal or distant metastases. The most significant predictor of outcome was extent of invasion. Eight-year RFS values for low- and high-risk groups were 100% and 24%. Corresponding rates of 8-year DSS were 100% and 58%.
Widely invasive HCC is an aggressive malignancy that identifies patients who are at high risk for recurrence and tumor-related death. Patients with HCC have a prognosis that is reliably predicted by degree of invasion, tumor size, extrathyroidal disease extension, and initial nodal or distant metastasis. Recurrence portends a poor outcome. High-risk patients and those with recurrence should be considered for adjuvant therapy. |
| doi_str_mv | 10.1007/BF02557374 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71507842</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1571791391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c242t-afe3d0b3217dde406a8ccaf47872cd864070f45d1210da5d27188efef58f9a163</originalsourceid><addsrcrecordid>eNpdkL1KA0EUhQdRTIw2PoAsFhbC6p3_jZ0GY4SAjdbLZOYObtifOJMF8252vpgTEgh4m3OLj8PHIeSSwh0F0PdPU2BSaq7FERlSyUUuVEGP0w-qyMdMyQE5i3EJQDUHeUoGlBbp9HhI8tnvT1h_1phZrOvMmmCrtmvMQ2YyBfkGTcjwe4WhwtbiOTnxpo54sc8R-Zg-v09m-fzt5XXyOM8tE2ydG4_cwYIzqp1DAcoU1hovdKGZdYUSoMEL6Sij4Ix0TCcf9Ohl4ceGKj4iN7veVei-eozrsqniVtC02PWx1FSCLgRL4PU_cNn1oU1uJWOaC5UUEnS7g2zoYgzoy1WoGhM2JYVyu2B5WDDBV_vGftGgO6D7yfgfsU9o_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227346217</pqid></control><display><type>article</type><title>Hürthle cell carcinoma: a 60-year experience</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Stojadinovic, Alexander ; Hoos, Axel ; Ghossein, Ronald A ; Urist, Marshall J ; Leung, Denis H Y ; Spiro, Ronald H ; Shah, Jatin P ; Brennan, Murray F ; Singh, Bhuvanesh ; Shaha, Ashok R</creator><creatorcontrib>Stojadinovic, Alexander ; Hoos, Axel ; Ghossein, Ronald A ; Urist, Marshall J ; Leung, Denis H Y ; Spiro, Ronald H ; Shah, Jatin P ; Brennan, Murray F ; Singh, Bhuvanesh ; Shaha, Ashok R</creatorcontrib><description>The aim of this study was to define the clinical behavior and prognostic indicators of outcome in Hürthle cell cancer (HCC).
Diagnosis was confirmed for 56 patients with HCC treated between 1940 and 2000, who form the basis of this study. Primary end points were relapse-free survival (RFS) and disease-specific survival (DSS). Data were analyzed with the Kaplan-Meier method and by log-rank test.
The extent of thyroid resection did not predict outcome. Recurrence was a significant predictor of tumor-related mortality. Significant adverse predictors of RFS and DSS were degree of invasion, size >4 cm, extrathyroidal extension, and initial nodal or distant metastases. The most significant predictor of outcome was extent of invasion. Eight-year RFS values for low- and high-risk groups were 100% and 24%. Corresponding rates of 8-year DSS were 100% and 58%.
Widely invasive HCC is an aggressive malignancy that identifies patients who are at high risk for recurrence and tumor-related death. Patients with HCC have a prognosis that is reliably predicted by degree of invasion, tumor size, extrathyroidal disease extension, and initial nodal or distant metastasis. Recurrence portends a poor outcome. High-risk patients and those with recurrence should be considered for adjuvant therapy.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1007/BF02557374</identifier><identifier>PMID: 11888879</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Adenoma, Oxyphilic - mortality ; Adenoma, Oxyphilic - pathology ; Adenoma, Oxyphilic - secondary ; Adenoma, Oxyphilic - therapy ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Analysis of Variance ; Child ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; New York City - epidemiology ; Prognosis ; Retrospective Studies ; Risk ; Survival Rate ; Thyroid Neoplasms - mortality ; Thyroid Neoplasms - pathology ; Thyroid Neoplasms - therapy ; Thyroidectomy</subject><ispartof>Annals of surgical oncology, 2002-03, Vol.9 (2), p.197-203</ispartof><rights>The Society of Surgical Oncology 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c242t-afe3d0b3217dde406a8ccaf47872cd864070f45d1210da5d27188efef58f9a163</citedby><cites>FETCH-LOGICAL-c242t-afe3d0b3217dde406a8ccaf47872cd864070f45d1210da5d27188efef58f9a163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11888879$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stojadinovic, Alexander</creatorcontrib><creatorcontrib>Hoos, Axel</creatorcontrib><creatorcontrib>Ghossein, Ronald A</creatorcontrib><creatorcontrib>Urist, Marshall J</creatorcontrib><creatorcontrib>Leung, Denis H Y</creatorcontrib><creatorcontrib>Spiro, Ronald H</creatorcontrib><creatorcontrib>Shah, Jatin P</creatorcontrib><creatorcontrib>Brennan, Murray F</creatorcontrib><creatorcontrib>Singh, Bhuvanesh</creatorcontrib><creatorcontrib>Shaha, Ashok R</creatorcontrib><title>Hürthle cell carcinoma: a 60-year experience</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><description>The aim of this study was to define the clinical behavior and prognostic indicators of outcome in Hürthle cell cancer (HCC).
Diagnosis was confirmed for 56 patients with HCC treated between 1940 and 2000, who form the basis of this study. Primary end points were relapse-free survival (RFS) and disease-specific survival (DSS). Data were analyzed with the Kaplan-Meier method and by log-rank test.
The extent of thyroid resection did not predict outcome. Recurrence was a significant predictor of tumor-related mortality. Significant adverse predictors of RFS and DSS were degree of invasion, size >4 cm, extrathyroidal extension, and initial nodal or distant metastases. The most significant predictor of outcome was extent of invasion. Eight-year RFS values for low- and high-risk groups were 100% and 24%. Corresponding rates of 8-year DSS were 100% and 58%.
Widely invasive HCC is an aggressive malignancy that identifies patients who are at high risk for recurrence and tumor-related death. Patients with HCC have a prognosis that is reliably predicted by degree of invasion, tumor size, extrathyroidal disease extension, and initial nodal or distant metastasis. Recurrence portends a poor outcome. High-risk patients and those with recurrence should be considered for adjuvant therapy.</description><subject>Adenoma, Oxyphilic - mortality</subject><subject>Adenoma, Oxyphilic - pathology</subject><subject>Adenoma, Oxyphilic - secondary</subject><subject>Adenoma, Oxyphilic - therapy</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis of Variance</subject><subject>Child</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>New York City - epidemiology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk</subject><subject>Survival Rate</subject><subject>Thyroid Neoplasms - mortality</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Thyroid Neoplasms - therapy</subject><subject>Thyroidectomy</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkL1KA0EUhQdRTIw2PoAsFhbC6p3_jZ0GY4SAjdbLZOYObtifOJMF8252vpgTEgh4m3OLj8PHIeSSwh0F0PdPU2BSaq7FERlSyUUuVEGP0w-qyMdMyQE5i3EJQDUHeUoGlBbp9HhI8tnvT1h_1phZrOvMmmCrtmvMQ2YyBfkGTcjwe4WhwtbiOTnxpo54sc8R-Zg-v09m-fzt5XXyOM8tE2ydG4_cwYIzqp1DAcoU1hovdKGZdYUSoMEL6Sij4Ix0TCcf9Ohl4ceGKj4iN7veVei-eozrsqniVtC02PWx1FSCLgRL4PU_cNn1oU1uJWOaC5UUEnS7g2zoYgzoy1WoGhM2JYVyu2B5WDDBV_vGftGgO6D7yfgfsU9o_Q</recordid><startdate>200203</startdate><enddate>200203</enddate><creator>Stojadinovic, Alexander</creator><creator>Hoos, Axel</creator><creator>Ghossein, Ronald A</creator><creator>Urist, Marshall J</creator><creator>Leung, Denis H Y</creator><creator>Spiro, Ronald H</creator><creator>Shah, Jatin P</creator><creator>Brennan, Murray F</creator><creator>Singh, Bhuvanesh</creator><creator>Shaha, Ashok R</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>200203</creationdate><title>Hürthle cell carcinoma: a 60-year experience</title><author>Stojadinovic, Alexander ; Hoos, Axel ; Ghossein, Ronald A ; Urist, Marshall J ; Leung, Denis H Y ; Spiro, Ronald H ; Shah, Jatin P ; Brennan, Murray F ; Singh, Bhuvanesh ; Shaha, Ashok R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c242t-afe3d0b3217dde406a8ccaf47872cd864070f45d1210da5d27188efef58f9a163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adenoma, Oxyphilic - mortality</topic><topic>Adenoma, Oxyphilic - pathology</topic><topic>Adenoma, Oxyphilic - secondary</topic><topic>Adenoma, Oxyphilic - therapy</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis of Variance</topic><topic>Child</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>New York City - epidemiology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk</topic><topic>Survival Rate</topic><topic>Thyroid Neoplasms - mortality</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Thyroid Neoplasms - therapy</topic><topic>Thyroidectomy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stojadinovic, Alexander</creatorcontrib><creatorcontrib>Hoos, Axel</creatorcontrib><creatorcontrib>Ghossein, Ronald A</creatorcontrib><creatorcontrib>Urist, Marshall J</creatorcontrib><creatorcontrib>Leung, Denis H Y</creatorcontrib><creatorcontrib>Spiro, Ronald H</creatorcontrib><creatorcontrib>Shah, Jatin P</creatorcontrib><creatorcontrib>Brennan, Murray F</creatorcontrib><creatorcontrib>Singh, Bhuvanesh</creatorcontrib><creatorcontrib>Shaha, Ashok R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stojadinovic, Alexander</au><au>Hoos, Axel</au><au>Ghossein, Ronald A</au><au>Urist, Marshall J</au><au>Leung, Denis H Y</au><au>Spiro, Ronald H</au><au>Shah, Jatin P</au><au>Brennan, Murray F</au><au>Singh, Bhuvanesh</au><au>Shaha, Ashok R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hürthle cell carcinoma: a 60-year experience</atitle><jtitle>Annals of surgical oncology</jtitle><addtitle>Ann Surg Oncol</addtitle><date>2002-03</date><risdate>2002</risdate><volume>9</volume><issue>2</issue><spage>197</spage><epage>203</epage><pages>197-203</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>The aim of this study was to define the clinical behavior and prognostic indicators of outcome in Hürthle cell cancer (HCC).
Diagnosis was confirmed for 56 patients with HCC treated between 1940 and 2000, who form the basis of this study. Primary end points were relapse-free survival (RFS) and disease-specific survival (DSS). Data were analyzed with the Kaplan-Meier method and by log-rank test.
The extent of thyroid resection did not predict outcome. Recurrence was a significant predictor of tumor-related mortality. Significant adverse predictors of RFS and DSS were degree of invasion, size >4 cm, extrathyroidal extension, and initial nodal or distant metastases. The most significant predictor of outcome was extent of invasion. Eight-year RFS values for low- and high-risk groups were 100% and 24%. Corresponding rates of 8-year DSS were 100% and 58%.
Widely invasive HCC is an aggressive malignancy that identifies patients who are at high risk for recurrence and tumor-related death. Patients with HCC have a prognosis that is reliably predicted by degree of invasion, tumor size, extrathyroidal disease extension, and initial nodal or distant metastasis. Recurrence portends a poor outcome. High-risk patients and those with recurrence should be considered for adjuvant therapy.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>11888879</pmid><doi>10.1007/BF02557374</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2002-03, Vol.9 (2), p.197-203 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71507842 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adenoma, Oxyphilic - mortality Adenoma, Oxyphilic - pathology Adenoma, Oxyphilic - secondary Adenoma, Oxyphilic - therapy Adolescent Adult Aged Aged, 80 and over Analysis of Variance Child Disease-Free Survival Female Humans Male Middle Aged New York City - epidemiology Prognosis Retrospective Studies Risk Survival Rate Thyroid Neoplasms - mortality Thyroid Neoplasms - pathology Thyroid Neoplasms - therapy Thyroidectomy |
| title | Hürthle cell carcinoma: a 60-year experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T01%3A06%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=H%C3%BCrthle%20cell%20carcinoma:%20a%2060-year%20experience&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Stojadinovic,%20Alexander&rft.date=2002-03&rft.volume=9&rft.issue=2&rft.spage=197&rft.epage=203&rft.pages=197-203&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1007/BF02557374&rft_dat=%3Cproquest_cross%3E1571791391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=227346217&rft_id=info:pmid/11888879&rfr_iscdi=true |